What AstralBio does

AstralBio is a privately held biotechnology company founded in 2023 and headquartered in Boston, Massachusetts. The company states a mission of developing best-in-class medicines to treat cardiometabolic and immune-mediated diseases, framing its work around two therapeutic verticals — cardiovascular and metabolic conditions on one hand, and immune-mediated disorders on the other. As of the available inputs, AstralBio has not disclosed any named therapeutic candidates, clinical programs, or pipeline assets.

The company's central technical claim is a machine learning-enabled platform intended to accelerate the progression of novel therapeutics. The platform is positioned as "proven" in source material, but no patents, publications, named models, datasets, or technical architecture details are disclosed. AstralBio was founded by former team members of ValenzaBio and AlmataBio, and its competitive positioning rests substantially on inherited antibody-development expertise from those prior organizations. The leadership team disclosed in the data consists of CEO Patrick Crutcher; no further executives, board members, or scientific staff are named.

Commercially, AstralBio is at the earliest formative stage. Revenue is not disclosed, no pricing or business model is described, and no customers, partners, or distribution channels are identified. The only financial event recorded is a single seed funding round of $957,408 closed on 2024-12-19. The company is therefore best characterized as a preclinical-stage platform biotech, with the ML platform and the founding team's antibody experience as its primary assets and with no commercial revenue, partnerships, or clinical-stage programs yet established.

Name

AstralBio

Legal name

AstralBio

Website

https://astralbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

AstralBio is a Boston-based, privately held biotechnology company founded in 2023 that uses a machine learning-enabled platform to develop novel therapeutics for cardiometabolic and immune-mediated diseases. It was founded by former ValenzaBio and AlmataBio antibody developers and is currently at preclinical stage.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)

Keywords

• Antibody therapeutics
• Cardiometabolic disease
• Immune-mediated therapies
• Machine learning drug discovery
• Biopharmaceutical development

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

AstralBio is a privately held biotechnology company developing best-in-class medicines to treat cardiometabolic and immune-mediated diseases. The company leverages a machine learning-enabled platform designed to accelerate the progression of novel therapeutics. Founded by former team members of ValenzaBio and AlmataBio, the company is currently operating in the drug discovery and development stage without named commercial therapeutic candidates.

Product overview

AstralBio is a privately held biotechnology company developing best-in-class medicines to treat cardiometabolic and immune-mediated diseases. The company leverages a machine learning-enabled platform to accelerate the progression of novel therapeutics. No specific named products, modules, or distinct service offerings are identified in the available source material — the company is presented as a therapeutic development pipeline without enumerated product SKUs or branded therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Recursion Pharmaceuticals: Publicly listed AI-driven drug discovery company combining ML and high-throughput biology; comparable as a broad incumbent in ML-enabled therapeutic discovery, though operates at much larger scale and broader therapeutic scope.
• Isomorphic Labs: Alphabet-backed AI drug-discovery company applying machine learning to therapeutic development; thematically comparable as a well-capitalized ML-drug-discovery peer with significantly greater resources.

Direct peers

• ValenzaBio: Antibody-focused biotech developing therapeutics for autoimmune and inflammatory diseases; AstralBio was founded by former ValenzaBio team members, making it a direct lineage peer with overlapping disease focus and antibody-engineering approach.
• AlmataBio: Antibody-development biotech co-founded by individuals who went on to found AstralBio; directly comparable as a predecessor antibody-platform company with shared scientific lineage.
• Generate Biomedicines: ML-enabled biologics discovery company developing novel antibody and protein therapeutics; the most direct category peer to AstralBio's stated ML-platform-plus-antibody-therapeutics model.
• BigHat Biosciences: Uses machine learning to engineer antibody therapeutics; comparable as an early-stage ML-for-antibody-design peer targeting similar therapeutic areas.
• AbCellera: AI-driven antibody discovery platform partnering with pharma to develop therapeutics; comparable technology stack (AI/ML-enabled antibody discovery) though at significantly larger scale and public-company stage.
• Adimab: Antibody discovery and engineering platform serving partners across multiple therapeutic areas; directly comparable as a platform-based antibody discovery company leveraging technology to accelerate development.

Emerging players

• Insitro: ML-driven drug discovery company applying machine learning to therapeutic development; comparable as an emerging platform peer using ML to compress timelines, though broader in therapeutic scope than AstralBio.
• Cradle Biosciences: Uses ML and generative protein design to engineer biologics including antibodies; comparable as an emerging platform peer in ML-enabled protein/antibody engineering.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AstralBio